Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 206

Sort by

Sort Order Select

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia

Steven P. Treon, Shayna Sarosiek, Jorge J. Castillo

Blood (2024) 143 (17): 1702–1712.

https://doi.org/10.1182/blood.2022017235

Published: 2024

Journal Articles

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Jorge J. Castillo, Andrew R. Branagan, David Sermer, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L. Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek

Blood (2024) 143 (7): 582–591.

https://doi.org/10.1182/blood.2023022420

Published: 2024

Includes: Supplemental data

Journal Articles

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Zachary R Hunter, Nickolas Tsakmaklis, Kris Richardson, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Ari M Melnick, Steven P Treon

Blood (2023) 142 (Supplement 1): 755.

https://doi.org/10.1182/blood-2023-190825

Published: 2023

Journal Articles

Establishment of the Bcwm.2 Cell Line As a BTK-Inhibitor Resistant, BCL2 Inhibitor Sensitive in Vitro and In Vivo Study Model for Waldenström's Macroglobulinemia

Shirong Liu, Xia Liu, Kara M Soroko, Alexa G Canning, Amanda Kofides, Choudhury Fabliha Binte Yusuf, Johany Penailillo, Nickolas Tsakmaklis, Christopher J Patterson, Ruben D. Carrasco, Zachary R Hunter, Prafulla C. Gokhale, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 6613.

https://doi.org/10.1182/blood-2023-190147

Published: 2023

Journal Articles

Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Waldenström Macroglobulinemia Initiating First-Line Treatment with Ibrutinib or Zanubrutinib

Jonas Paludo, Shayna R Sarosiek, Gottfried R. von Keudell, Monika Salkar, Summera Zhou, Sonia Kim, Ning Cheng, Michelle Pacia, Sudeep Karve, Jorge J. Castillo

Blood (2023) 142 (Supplement 1): 7385.

https://doi.org/10.1182/blood-2023-181053

Published: 2023

Journal Articles

Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Blood (2023) 142 (Supplement 1): 2422.

https://doi.org/10.1182/blood-2023-190477

Published: 2023

Journal Articles

Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance

Shirong Liu, Amanda Kofides, Xia Liu, Alexa G Canning, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Zachary R Hunter, Kris Richardson, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy P. White, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 3300.

https://doi.org/10.1182/blood-2023-190463

Published: 2023

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1775.

https://doi.org/10.1182/blood-2023-188015

Published: 2023

Journal Articles

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

Shayna R Sarosiek, Andrew R. Branagan, Christopher Doughty, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Kirsten Meid, Steven P Treon, Jorge J. Castillo

Blood (2023) 142 (Supplement 1): 213.

https://doi.org/10.1182/blood-2023-185113

Published: 2023

Journal Articles

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Kris Richardson, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2023-190631

Published: 2023

Journal Articles

Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia

Shayna R Sarosiek, Gottfried R. von Keudell, Jonas Paludo, Monika Salkar, Barnabie Agatep, Anjali Franco, Samuel Crawford, Michelle Pacia, Jorge J. Castillo

Blood (2023) 142 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2023-181925

Published: 2023

Journal Articles

Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR ) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1757.

https://doi.org/10.1182/blood-2023-188265

Published: 2023

Journal Articles

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Eric Durot, Damien Roos-Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Hedi Bensader, Morgane Cheminant, Caroline Jacquet, Stephanie Guidez, François-Xavier Gros, Emmanuel Bachy, Pascale Cony-Makhoul, Steven P Treon, Alain Jacques Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot

Blood (2023) 142 (Supplement 1): 616.

https://doi.org/10.1182/blood-2023-173988

Published: 2023

Journal Articles

Novel Protacs Demonstrate Dual Kinase Inhibition and Degradation of HCK and BTK, and Are Highly Active in MYD88 Mutated WM and ABC DLBCL Cells

Shirong Liu, John M Hatcher, Amanda Kofides, Alexa G Canning, Jinhua Wang, Xia Liu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Zachary R Hunter, Shayna R Sarosiek, Jorge J. Castillo, Sara J. Buhrlage, Steven P Treon

Blood (2023) 142 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2023-190369

Published: 2023

Journal Articles

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Alexa G Canning, Kris Richardson, Maria Luisa Guerrera, Christopher J Patterson, Kirsten Meid, Timothy P. White, Megan Little, Katherine Stockman, Joshua Gustine, Catherine A. Flynn, Andrew R. Branagan, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 211.

https://doi.org/10.1182/blood-2023-190520

Published: 2023

Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2023-174294

Published: 2023

Journal Articles

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2023-187237

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

NARROW

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Establishment of the Bcwm.2 Cell Line As a BTK-Inhibitor Resistant, BCL2 Inhibitor Sensitive in Vitro and In Vivo Study Model for Waldenström's Macroglobulinemia

Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Waldenström Macroglobulinemia Initiating First-Line Treatment with Ibrutinib or Zanubrutinib

Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Novel Protacs Demonstrate Dual Kinase Inhibition and Degradation of HCK and BTK, and Are Highly Active in MYD88 Mutated WM and ABC DLBCL Cells

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only